Bladder Cancer: Treatment in the Metastatic Setting

Opinion
Video

Focusing on the metastatic setting, the expert panel discusses advanced kidney cancer treatment practices, highlighting recent data that are informing treatment decisions.

Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Related Content
In patients who refuse or are ineligible for radical cystectomy, the gemcitabine intravesical system may be given after unsuccessful BCG treatment.

FDA Approves Gemcitabine Intravesical System in BCG-Unresponsive NMIBC

Ariana Pelosci
September 9th 2025
Article

In patients who refuse or are ineligible for radical cystectomy, the gemcitabine intravesical system may be given after unsuccessful BCG treatment.

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

In July 2025, the FDA granted priority review to TAR-200 in patients with BCG-unresponsive high-risk NMIBC.3

TAR-200 Appears Highly Efficacious, Safe in BCG-Unresponsive NMIBC

Tim Cortese
August 15th 2025
Article

Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

FDA Grants Priority Review to TAR-200 in BCG-Unresponsive High-Risk NMIBC

FDA Grants Priority Review to TAR-200 in BCG-Unresponsive High-Risk NMIBC

Ariana Pelosci
July 17th 2025
Article

Phase 2b SunRISe-1 trial findings supported the FDA to grant priority review to TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.